@Supermatt Bub has secured entry to US then why can't it get approved to China? Is chinese health standards more rigorous than US? I am not sure if you have listened to strategic review webcast. It is clearly mentioned that despite it being costly and time consuming process, company will still work for obtaining SAMR approval. Also they mentioned that unlike the previous management putting all eggs in one basket, they will supply to China with multiple channels and multiple suppliers. With all those initiatives, I am assuming revenue from China will significantly increase in 2023-24. Also revenue from US will significantly increase as per recent surge in sell on amazon and other platforms.
BUB Price at posting:
23.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)